Cyclo Therapeutics (CYTH) - Net earnings per share (EPS TTM)

Symbol and logo of brand cyclotherapeutics.com (CYTH)

Cyclo Therapeutics (CYTH) is building an ecosystem of cyclodextrin-based drugs and holds FDA breakthrough therapy designation. Partnerships with institutes are accelerating the development of the drug Trappsol Cyclo. The trailing 12-month EPS on the GURU.Markets chart demonstrates that the metric remains at -0.90. Cyclo Therapeutics is diversifying its risks by focusing on the treatment of rare genetic pathologies of the brain and blood vessels.

CYTH (cyclotherapeutics.com) Earnings per share for the last 12 months history from 07/04/2022 to 04/05/2025

Comprehensive metric breakdowns and analytics for CTD Holdings (CYTH)

- share price and expert price forecast:
General company analysis:cyclotherapeutics.com (CYTH)
Mass-produced product of Cyclo Therapeutics Inc.

This indicator measures the portion of net income attributable to a single common share, reflecting the actual efficiency of capital generation. By analyzing the trailing twelve-month earnings per share, an investor can observe current business dynamics without the delays associated with quarterly reporting. The calculation is based on the sum of profits over the last 12 months, adjusted for the total number of securities. For Cyclo Therapeutics (CYTH), the stability of this metric is supported by long-term agreements with international laboratories. Reliable supply chain logistics for chemical compounds minimize operational risks, ensuring the predictability of financial results.

Competitors of Cyclo Therapeutics (CYTH)

VRTX: Net earnings per share for the last 12 months|Earnings per one share for the last 12 months ALNY|INSM: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months United Therapeutics Corp. (UTHR)|BMRN (BioMarin) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BBIO (BridgeBio)|Earnings per share for the last twelve months bgm.ltd (BGM)|COGT (Cogent Biosciences Inc) - Earnings per share for the trailing year|Earnings per share for the last twelve months Xeris Biopharma Holdings XERS|KROS (Keros Pharma) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|CMMB: Net earnings per share (EPS TTM)|SRx Health Solutions Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Polyrizon Ltd|AEZS (Aeterna Zentaris) - Earnings per share for the last four quarters|Net earnings per share for the last 12 months INZY (inozyme.com)|RPHM - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CSCI (cosciensbio.com)